AIM2 and colorectal carcinoma: Furthermore, we also established the BRAF-mutant PDOs and demonstrated that overexpressed AIM2 could significantly inhibit the development of CRC with BRAF mutation, suggesting that pharmacological activation of AIM2 may be beneficial in BRAF-mutant CRC patients.